Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Videos
Diagnostics
In Vitro Diagnostics
Return to: MDBR Home | Diagnostics | In Vitro Diagnostics

ADL launches urine-based diagnostic test to detect precursor to colorectal cancer

MDBR Staff Writer Published 29 June 2016

Atlantic Diagnostic Laboratories (ADL) announced the official launch of PolypDx, a non-invasive urine-based diagnostic test for detection of adenomatous polyps, the precursor to colorectal cancer. It is estimated that there will be 134,490 new cases reported this year.

With early detection in the adenomatous polyp stage, this form of cancer is preventable. Early detection will save lives and reduce treatment costs.

"ADL, with its extensive LC/MS/MS expertise, is very excited to be offering the PolypDx™ non-invasive urine test for its official launch into America," said Aaron Domenico, Chief Operating Officer of ADL.

"Colorectal cancer is a leading cause of death in the United States. With early detection in the adenomatous polyp stage, this form of cancer is preventable."

PolypDx™ gives doctors a new tool in the prevention of colorectal cancer. In a Canadian-based clinical trial of nearly 1,000 patients, MTI's PolypDx™ demonstrated significantly higher sensitivity than current fecal-based screening tests to detect adenomatous polyps.

Once screened, patients presenting a risk of adenomatous polyps can be directed to a colonoscopy, during which the adenomatous polyps can be completely and safely removed, thus preventing the progression into colorectal cancer.

PolypDx™ is a simple and effective test requiring only a small urine sample. Early detection and non-invasive ease of use are key distinguishing factors for a screening test in the prevention of colorectal cancer.

PolypDx™ is the flagship product of Metabolomic Technologies Inc. (MTI), a privately held Canadian company based in Edmonton, Alberta. MTI has signed a multi-million dollar agreement with ADL giving them the exclusive licensing and distribution rights to bring PolypDx™ into the US market.

"The partnership and collaboration between MTI and Atlantic Diagnostic Laboratories will provide the opportunity for patients to access a simple and accurate test with proven capacity to detect adenomatous colonic polyps and thereby prevent colon cancer," said Dr. Richard Fedorak, President of MTI.

ADL is a full service clinical laboratory with headquarters in the suburbs of Philadelphia providing microbiology, chemistry, toxicology, immunology, virology and molecular testing in 12 states: Pennsylvania, New Jersey, Connecticut, New York, District of Columbia, Delaware, Maryland, Virginia, Florida, Ohio, Kentucky and West Virginia.



Source: Company Press Release